The guidelines state, GLP-1 RAs may be considered for weight-loss in patients who have completed cancer therapy and may be considered with caution for patients on stable endocrine-based cancer therapies based on limited observational safety data. They also say, GLP-1 RAs cannot be recommended currently for patients receiving or initiating chemotherapies and/or immunotherapies due to lack of safety and outcomes data. Iyengar is director of Survivorship Services at Winship Cancer Institute of Emory University, a clinical member of Winships Glenn Family Breast Center, an associate professor and co-director of the Breast Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, and co-editor-in-chief of the journal ONCOLOGY
He currently serves as the Chief Academic Officer and Dean of Graduate Studies at Lionel University
Several theoretical mechanisms have been proposed, though none are conclusively proven
For in vitro research use only.
Nausea is most pronounced during the initial weeks of GLP-1 treatment and typically diminishes significantly after 24 weeks as your body adapts to the medication
Meanwhile, Lilly will also be required to demonstrate the clinical and economic benefits brought about by Zepbound's high efficacy (such as the prevention of diabetes onset and productivity improvements through the improvement of sleep apnea syndrome) with evidence
